Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Florham Park New Jersey-based company is expected to report a 392.6% increase in revenue to $36.077 million from $7.32 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Phathom Pharmaceuticals Inc is for a loss of $1.04 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $18.50, about 53.3% above its last closing price of $8.64
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.15 | -1.15 | -1.31 | Missed | -14.2 |
Dec. 31 2025 | -1.31 | -1.27 | -1.05 | Beat | 17.4 |
Sep. 30 2024 | -1.59 | -1.49 | -1.32 | Beat | 11.7 |
Jun. 30 2024 | -1.40 | -1.38 | -1.56 | Missed | -13 |
Mar. 31 2024 | -1.28 | -1.31 | -1.42 | Missed | -8.5 |
Dec. 31 2023 | -1.10 | -1.08 | -1.39 | Missed | -29.1 |
Sep. 30 2023 | -0.87 | -0.89 | -0.76 | Beat | 14.7 |
Jun. 30 2023 | -0.94 | -0.98 | -0.84 | Beat | 14.2 |
This summary was machine generated August 5 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)